Cardio Diagnostics Holdings Inc
CDIO
查看详细走势图
1.290USD
+0.240+22.86%
收盘 02/06, 16:00（美东）报价延迟15分钟
2.28M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+22.86%
5天
-14.57%
1月
-56.35%
6月
-67.26%
今年开始到现在
-52.40%
1年
-90.52%
查看详细走势图
TradingKey Cardio Diagnostics Holdings Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Cardio Diagnostics Holdings Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名232/392位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价60.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cardio Diagnostics Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Cardio Diagnostics Holdings Inc亮点
亮点风险
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
业绩高增长
公司营业收入稳步增长，连续3年增长3572.63%
业绩增长期
公司处于发展阶段，最新年度总收入34.89K美元
利润高增长
公司净利润处于行业前列，最新年度总收入34.89K美元
估值高估
公司最新PE估值-0.40，处于3年历史高位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值24.12K
分析师目标
根据
0
位分析师
--
评级
60.000
目标均价
+1227.43%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cardio Diagnostics Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cardio Diagnostics Holdings Inc简介
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
公司代码CDIO
公司Cardio Diagnostics Holdings Inc
CEODogan (Meeshanthini V)
网址
相关品种
